PAX9 in Cancer Development

Int J Mol Sci. 2022 May 17;23(10):5589. doi: 10.3390/ijms23105589.

Abstract

Paired box 9 (PAX9) is a transcription factor of the PAX family functioning as both a transcriptional activator and repressor. Its functional roles in the embryonic development of various tissues and organs have been well studied. However, its roles and molecular mechanisms in cancer development are largely unknown. Here, we review the current understanding of PAX9 expression, upstream regulation of PAX9, and PAX9 downstream events in cancer development. Promoter hypermethylation, promoter SNP, microRNA, and inhibition of upstream pathways (e.g., NOTCH) result in PAX9 silencing or downregulation, whereas gene amplification and an epigenetic axis upregulate PAX9 expression. PAX9 may contribute to carcinogenesis through dysregulation of its transcriptional targets and related molecular pathways. In summary, extensive studies on PAX9 in its cellular and tissue contexts are warranted in various cancers, in particular, HNSCC, ESCC, lung cancer, and cervical SCC.

Keywords: PAX9; cancer.

Publication types

  • Review

MeSH terms

  • Head and Neck Neoplasms* / genetics
  • Humans
  • PAX9 Transcription Factor* / genetics
  • PAX9 Transcription Factor* / metabolism
  • Promoter Regions, Genetic
  • Squamous Cell Carcinoma of Head and Neck / genetics
  • Transcription Factors / metabolism

Substances

  • PAX9 Transcription Factor
  • PAX9 protein, human
  • Transcription Factors